Reuters logo
BRIEF-Reata announces initiation of phase 2/3 study of bardoxolone methyl in treatment of chronic kidney disease
February 23, 2017 / 2:33 PM / 7 months ago

BRIEF-Reata announces initiation of phase 2/3 study of bardoxolone methyl in treatment of chronic kidney disease

Feb 23 (Reuters) - Reata Pharmaceuticals Inc:

* Reata announces initiation of phase 2/3 study of bardoxolone methyl in the treatment of chronic kidney disease due to alport syndrome

* Reata pharmaceuticals inc - expects data from phase 2 portion of trial to be available, and to decide on entering phase 3 portion, by year-end 2017

* Reata pharmaceuticals inc says phase 2 portion of study is open-label and will enroll up to 30 patients from 12 to 60 years old

* Reata pharmaceuticals inc - based on fda guidance, if trial is positive, year one off-treatment data could support accelerated approval

* Reata pharmaceuticals inc - based on fda guidance, year two off-treatment data could support full approval Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below